Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Parexel Reports Strong CRO Business

By Drug Discovery Trends Editor | January 26, 2010

NEW YORK (AP) – Shares of Parexel International Corp. climbed to an annual high after the pharmaceutical research contractor said it is winning more business than it previously expected, and raised its estimates for the fiscal year.

The Waltham, Mass., company said its drug development and late-stage clinical testing are doing more business in all regions. Both of those divisions took a hit as the economy slumped and drugmakers cut back on their spending. Parexel’s orders were stronger than expected during the December quarter, as the company said it received $141 in orders for every $100 in orders it filled.

Analysts said the company previously expected a ratio of $125 in new orders per $100 that were filled.

In afternoon trading, Parexel stock rose $3.18, or 18 percent, to $20.72. Earlier it peaked at $21.10, the stock’s highest price since October 2008.

Jefferies & Co. analyst David Windley said Parexel is benefiting from recent mergers among drugmakers, including last year’s tie-ups between Pfizer Inc. and Wyeth, and Merck & Co. and Schering-Plough Corp., along with new partnerships, increased outsourcing, and more funding from biotechnology companies as the economy improves.

Windley said Parexel’s comments about the drug development and late-stage businesses are “the first time we have heard such a positive statement regarding demand.” He said the company is in position to report stronger profit and revenue growth than its rivals for the rest of the year.

Windley kept a “Buy” rating on Parexel shares.

Meanwhile, Raymond James analyst Alexander Draper upgraded the stock to “Outperform” from “Market Perform.” Both analysts have price targets of $20 per share.

For the current fiscal year, which ends in June, Parexel raised its profit forecast to a range of $1 to $1.06 per share from 90 cents to $1 per share, and it now expects $1.13 billion to $1.15 billion in revenue, from $1.12 billion to $1.15 billion. It also gave a third-quarter outlook that was slightly above analyst expectations.

Date: January 26, 2010
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50